Analysts Set Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Target Price at $71.90

Share on StockTwits

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has been assigned an average recommendation of “Buy” from the thirteen ratings firms that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $71.80.

A number of research analysts recently issued reports on BHVN shares. ValuEngine downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Wednesday, June 19th. Morgan Stanley set a $50.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “hold” rating in a research note on Friday, August 9th. Goldman Sachs Group started coverage on shares of Biohaven Pharmaceutical in a research note on Monday, May 6th. They issued a “buy” rating and a $92.00 price target for the company. Oppenheimer set a $68.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, June 19th. Finally, Piper Jaffray Companies lifted their price target on shares of Biohaven Pharmaceutical from $75.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 8th.

In other Biohaven Pharmaceutical news, Director John W. Childs bought 10,000 shares of the business’s stock in a transaction dated Wednesday, June 26th. The shares were acquired at an average cost of $40.37 per share, with a total value of $403,700.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO James Engelhart bought 2,500 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was acquired at an average cost of $43.05 per share, for a total transaction of $107,625.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 17,500 shares of company stock worth $712,425. 23.90% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. Asset Management One Co. Ltd. purchased a new stake in shares of Biohaven Pharmaceutical in the 2nd quarter worth about $1,572,000. Laurion Capital Management LP purchased a new stake in shares of Biohaven Pharmaceutical in the 2nd quarter worth about $3,709,000. Tower Research Capital LLC TRC purchased a new stake in shares of Biohaven Pharmaceutical in the 2nd quarter worth about $65,000. L & S Advisors Inc boosted its position in shares of Biohaven Pharmaceutical by 93.0% in the 2nd quarter. L & S Advisors Inc now owns 81,868 shares of the company’s stock worth $3,585,000 after buying an additional 39,446 shares in the last quarter. Finally, Ardsley Advisory Partners LP boosted its position in shares of Biohaven Pharmaceutical by 2,505.0% in the 2nd quarter. Ardsley Advisory Partners LP now owns 260,500 shares of the company’s stock worth $11,415,000 after buying an additional 250,500 shares in the last quarter. Hedge funds and other institutional investors own 85.14% of the company’s stock.

Shares of Biohaven Pharmaceutical stock opened at $38.83 on Friday. Biohaven Pharmaceutical has a 52-week low of $29.17 and a 52-week high of $67.86. The business has a 50 day moving average price of $42.69. The stock has a market capitalization of $1.74 billion, a P/E ratio of -6.31 and a beta of 0.24.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.26). As a group, sell-side analysts predict that Biohaven Pharmaceutical will post -6.26 EPS for the current fiscal year.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Article: Should you buy a closed-end mutual fund?

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
SB Financial Group Inc  Shares Bought by EJF Capital LLC
SB Financial Group Inc Shares Bought by EJF Capital LLC


© 2006-2019 Ticker Report